Long-term evaluation of the efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous foaters
- PMID: 36169439
- PMCID: PMC11575750
- DOI: 10.5935/0004-2749.2021-0395
Long-term evaluation of the efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous foaters
Abstract
Purpose: This study aimed to evaluate the long-term safety and efficacy of neodymium-doped yttrium aluminum garnet (Nd:YAG) vitreolysis for symptomatic vitreous floaters as it remains a controversial procedure due to insufficient robust evidence in the literature for the maintenance of the results and absence of adverse effects.
Methods: This is an observational extension to the previously presented prospective, randomized, double-blind clinical trial. Eight of thirteen subjects who underwent vitreolysis with YAG laser returned for a late reevaluation, 18 months after the procedure, to evaluate the efficacy and safety of the procedure.
Results: All patients maintained the improvement in symptomatology noted after the procedure, with 25% showing complete improvement and a similar proportion (37.5%) reporting significant or partial improvement. Objective improvement in opacity was similar to that found at 6 months follow-up. The NEI-VFQ 25 quality of life questionnaire showed no statistically significant difference in responses between the 6th and 18th month. No adverse effects were noted on clinical examination or reported by patients.
Conclusion: Vitreolysis efficacy observed at 6 months of follow-up was maintained until the eighteenth month, with all patients reporting improvement from the pre-procedure state. No late adverse effects were noted. A larger randomized clinical trial is needed to confirm the safety of the procedure.
Objetivos: Avaliar a segurança e eficácia a longo prazo da vitreólise com Nd:YAG laser para moscas volantes sintomáticas, uma vez que permanece como um procedimento controverso devido a falta de evidência científica robusta sobre a manutenção dos resultados e ocorrência de efeitos adversos.
Métodos: Este estudo é uma extensão observacional de um ensaio clínico prospectivo, randomizado, duplo cego, previamente publicado. Oito de treze pacientes que foram submetidos a vitreólise com YAG laser foram acompanhados para uma reavaliação tardia, dezoito meses após o procedimento, para avaliar a eficácia e segurança do procedimento.
Resultados: Todos os pacientes mantiveram a melhora na sintomatologia notada ao final do procedimento original, com 25% dos casos apresentando melhora completa, e uma proporção semelhante (37,5%) demonstrando melhora significativa ou parcial. A melhora objetiva na opacidade foi similar ao achado no seguimento original de 6 meses. O questionário de qualidade de vida NEI-VFQ 25 não demonstrou diferença estatisticamente significativa nas respostas entre o sexto e o décimo oitavo mês de acompanhamento. Nenhum efeito adverso foi notado no exame clínico ou reportado pelos pacientes.
Conclusão: A eficácia da vitreólise observada ao sexto mês do acompanhamento foi mantida até o décimo oitavo mês, com todos os pacientes notando algum grau de melhora quando comparado ao estado pré procedimento. Nenhum efeito adverso tardio foi notado. Um ensaio clínico randomizado maior é necessário para confirmar a segurança do procedimento.
Conflict of interest statement
Similar articles
-
Efficacy and safety of early YAG laser vitreolysis for symptomatic vitreous floaters: the study protocol for a randomized clinical trial.Trials. 2024 Jan 13;25(1):48. doi: 10.1186/s13063-024-07924-1. Trials. 2024. PMID: 38218919 Free PMC article.
-
Assessment of Vitreous Structure and Visual Function after Neodymium:Yttrium-Aluminum-Garnet Laser Vitreolysis.Ophthalmology. 2019 Nov;126(11):1517-1526. doi: 10.1016/j.ophtha.2019.06.021. Epub 2019 Jun 22. Ophthalmology. 2019. PMID: 31471088 Free PMC article.
-
Efficacy and safety of yttrium-aluminium garnet (YAG) laser vitreolysis for vitreous floaters.J Int Med Res. 2018 Nov;46(11):4465-4471. doi: 10.1177/0300060518794245. Epub 2018 Sep 10. J Int Med Res. 2018. PMID: 30200800 Free PMC article. Clinical Trial.
-
Laser vitreolysis for symptomatic floaters is not yet ready for widespread adoption.Surv Ophthalmol. 2020 Sep-Oct;65(5):589-591. doi: 10.1016/j.survophthal.2020.02.007. Epub 2020 Mar 3. Surv Ophthalmol. 2020. PMID: 32135173 Review.
-
Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview.Adv Ther. 2020 Apr;37(4):1319-1327. doi: 10.1007/s12325-020-01261-w. Epub 2020 Feb 21. Adv Ther. 2020. PMID: 32086749 Free PMC article. Review.
Cited by
-
Management of Visually Significant Vitreous Opacities.Mo Med. 2024 Sep-Oct;121(5):391-394. Mo Med. 2024. PMID: 39421475 Free PMC article. Review.
-
Design of a Functional Eye Dressing for Treatment of the Vitreous Floater.J Pers Med. 2022 Oct 5;12(10):1659. doi: 10.3390/jpm12101659. J Pers Med. 2022. PMID: 36294798 Free PMC article.
-
Efficacy and safety of early YAG laser vitreolysis for symptomatic vitreous floaters: the study protocol for a randomized clinical trial.Trials. 2024 Jan 13;25(1):48. doi: 10.1186/s13063-024-07924-1. Trials. 2024. PMID: 38218919 Free PMC article.
References
-
- Milston R, Madigan MC, Sebag J. Vitreous floaters: Etiology, diagnostics, and management. Surv Ophthalmol. 2016;61(2):211–227. - PubMed
-
- Lumi X, Hawlina M, Glavač D, Facskó A, Moe MC, Kaarniranta K, et al. Ageing of the vitreous: from acute onset floaters and flashes to retinal detachment. Ageing Res Rev. 2015;21:71–77. - PubMed
-
- Garcia GA, Khoshnevis M, Yee KM, Nguyen-Cuu J, Nguyen JH, Sebag J. Degradation of contrast sensitivity function following posterior vitreous detachment. Am J Ophthalmol. 2016;172:7–12. - PubMed
-
- Cohen MN, Rahimy E, Ho AC, Garg SJ. Management of symptomatic floaters: current attitudes, beliefs, and practices among vitreoretinal surgeons. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):859–865. - PubMed
-
- Wagle AM, Lim WY, Yap TP, Neelam K, Au Eong KG. Utility values associated with vitreous floaters. Am J Ophthalmol. 2011;152(1):60–65.:e1. - PubMed